Form 4: QuidelOrtho CTO Vests RSUs, Sells Shares for Tax

QuidelOrtho's EVP of R&D & CTO, Jonathan Siegrist, acquired 18,656 common shares through RSU vesting and sold 6,676 shares to cover tax obligations.

Summary

• Jonathan Philip Siegrist, EVP of R&D & CTO of QuidelOrtho Corp (QDEL), reported changes in his beneficial ownership.
• On October 15, 2025, 18,656 restricted stock units (RSUs) vested, resulting in the acquisition of 18,656 shares of common stock at a price of $0.
• Concurrently, 6,676 shares of common stock were disposed of on October 15, 2025, at a price of $27.31 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Siegrist directly beneficially owns 11,980 shares of common stock.
• Additionally, 37,314 derivative restricted stock units remain beneficially owned, with future vesting scheduled in equal installments on October 15, 2026, and October 15, 2027.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects a routine, pre-planned compensation event for an executive, indicating continued alignment of interests. The sale of shares is for tax purposes, which is a neutral, expected outcome of RSU vesting.

Positives

• The vesting of 18,656 restricted stock units demonstrates the company's commitment to long-term incentive compensation for its executives, aligning management interests with shareholder value.
• The acquisition of shares through RSU vesting increases the executive's direct ownership in the company, signaling confidence.

Negatives

• The disposition of 6,676 shares, while for tax purposes, reduces the executive's direct beneficial ownership of common stock.

Future Outlook

The remaining 37,314 restricted stock units held by Jonathan Siegrist are scheduled to vest in equal installments on October 15, 2026, and October 15, 2027, indicating continued long-term incentive alignment.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of restricted stock units and a subsequent sale of shares to cover tax liabilities. Such transactions are common across all industries for publicly traded companies that utilize equity-based compensation plans.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across the healthcare and diagnostics industry, similar to companies like Abbott Laboratories, Danaher Corporation, and Thermo Fisher Scientific.
• The sale of shares to cover tax withholding obligations upon RSU vesting is a typical and expected event, consistent with compensation practices observed in comparable companies.

Stakeholder Impact

• Shareholders gain transparency into executive compensation and ownership changes, which can influence perceptions of management alignment and commitment.
• Employees, particularly other executives, may view this as a standard and expected part of their own equity compensation plans.

Next Steps

• Future vesting of 37,314 restricted stock units in equal installments on October 15, 2026, and October 15, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled insider transaction related to executive compensation (RSU vesting and tax-related share sale). It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation and does not signal any fundamental shift in the company's outlook.

Keywords

QuidelOrtho, QDEL, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Sale, Tax Withholding